and hDM2 and Characterization of the Confirmed Hits Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53

[1]  P. Wipf,et al.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. , 2009, Assay and drug development technologies.

[2]  G. Selivanova,et al.  Tumor-specific induction of apoptosis by a p53-reactivating compound. , 2009, Experimental cell research.

[3]  Peter Wipf,et al.  Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. , 2008, Assay and drug development technologies.

[4]  W. El-Deiry,et al.  Restoration of p53 to limit tumor growth , 2008, Current opinion in oncology.

[5]  Michael C. Myers,et al.  HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. , 2007, Assay and drug development technologies.

[6]  Hong Zhang,et al.  A High-Throughput Screen Measuring Ubiquitination of p53 by Human mdm2 , 2007, Journal of biomolecular screening.

[7]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[8]  P. Wipf,et al.  Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. , 2007, Assay and drug development technologies.

[9]  Michael R. Green,et al.  Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome , 2007, Journal of Molecular Medicine.

[10]  J. Lazo,et al.  Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. , 2007, Cancer research.

[11]  B. K. Lundholt,et al.  A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions. , 2006, Assay and drug development technologies.

[12]  Baoli Hu,et al.  MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin* , 2006, Journal of Biological Chemistry.

[13]  Mengjia Tang,et al.  Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.

[14]  D. Green,et al.  Dissecting p53-dependent apoptosis , 2006, Cell Death and Differentiation.

[15]  K. Wiman,et al.  Strategies for therapeutic targeting of the p53 pathway in cancer , 2006, Cell Death and Differentiation.

[16]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Wiman,et al.  Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs* , 2005, Journal of Biological Chemistry.

[18]  Ronen Marmorstein,et al.  Acridine derivatives activate p53 and induce tumor cell death through bax , 2005, Cancer biology & therapy.

[19]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[20]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[21]  M. Demma,et al.  CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73* , 2004, Journal of Biological Chemistry.

[22]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[23]  W. El-Deiry,et al.  Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.

[24]  M. Rolfe,et al.  Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[26]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[27]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[28]  Bo Xu,et al.  Involvement of Brca1 in S-Phase and G2-Phase Checkpoints after Ionizing Irradiation , 2001, Molecular and Cellular Biology.

[29]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[30]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[31]  O. Stål,et al.  Overexpression of MDM2 in acute childhood lymphoblastic leukemia. , 1998, Pediatric hematology and oncology.

[32]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[33]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[34]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[35]  C. Harris,et al.  p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.

[36]  H. Findley,et al.  Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia , 2000, Leukemia.